<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344629</url>
  </required_header>
  <id_info>
    <org_study_id>1235.28</org_study_id>
    <nct_id>NCT01344629</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use</brief_title>
  <official_title>Bioequivalence of Telmisartan Administrated in Two Different Ways: Both in Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Telmisartan 80 mg Tablet and Amlodipine 5mg Tablet in Concomitant Use in Healthy Male Volunteers. (an Open-label, Randomized, Single-dose, Four-period Replicated Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the bioequivalence of telmisartan administrated in two different ways: both in
      telmisartan 80 mg/amlodipine 5 mg fixed-dose combination tablets (T) and as telmisartan 80 mg
      tablet and amlodipine 5 mg tablets (R) in concomitant use
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
    <description>Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
    <description>maximum measured concentration of Telmisartan in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
    <description>area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
    <description>time from dosing to the maximum concentration of Telmisartan in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
    <description>terminal rate constant of Telmisartan in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
    <description>terminal half-life of Telmisartan in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
    <description>mean residence time of Telmisartan in the body after oral administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan80mg/Amlodipin5mg FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose, four-period replicated crossover design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan80mgtab + Amlodipin5mg tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose, four-period replicated crossover design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipin FDC</intervention_name>
    <description>Telmisartan80mg/Amlodipin5mg FDC</description>
    <arm_group_label>Telmisartan80mg/Amlodipin5mg FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 80 mg tablet</description>
    <arm_group_label>Telmisartan80mgtab + Amlodipin5mg tab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipin</intervention_name>
    <description>Amlodipin 5mg tablet</description>
    <arm_group_label>Telmisartan80mgtab + Amlodipin5mg tab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Without any clinically significant findings and complications on the basis of a
             complete medical history, including the physical examination, vital signs (blood
             pressure, pulse rate, body temperature), 12-lead electrocardiograms (ECGs), clinical
             laboratory tests

          2. Age: =20 and =35 years

          3. Body weight: =50 kg and =80 kg

          4. Body mass index (BMI): =18.0 and =25.0 kg/m2

        Exclusion criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          2. Diseases of the central nervous system (such as epilepsy) or psychiatric or
             neurological disorders

          3. Chronic or relevant acute infections

          4. Any clinical relevant findings in laboratory test results deviating from normal

          5. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)
             antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test

          6. History of surgery of the gastrointestinal tract (except appendectomy)

          7. History of relevant orthostatic hypotension, fainting spells, or blackouts

          8. Known hypersensitivity to any component of the formulation (telmisartan and
             amlodipine), to any other angiotensin receptor blocker, or to any other
             dihydropyridine calcium channel blocker compound

          9. Intake of drugs with a long half-life (=24 hours) within at least 1 month or less than
             10 half-lives of the respective drug before drug administration

         10. Intake of drugs which might reasonably influence the results of the trial on the basis
             of the knowledge at the time of protocol preparation within 7 days before drug
             administration

         11. Participation in another trial with an investigational drug within 1 months or less
             than 10 times of half-lives of the investigational products before drug administration

         12. Smoker (=20 cigarettes/day)

         13. Alcohol abuse (60 g or more ethanol/day: e.g., 3 middle-sized bottles of beer, 3 gous
             [equivalent to 540 mL] of sake)

         14. Drug abuse

         15. Blood donation (more than 100 mL within 4 weeks before drug administration)

         16. Excessive physical activities (ex. Marathon etc) within 1 week before drug
             administration

         17. Intake of alcohol within 2 days before drug administration

         18. Inability to comply with dietary regimen of the study site

         19. Inability to refrain from smoking during trial days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.28.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <results_first_submitted>July 10, 2012</results_first_submitted>
  <results_first_submitted_qc>August 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence A</title>
          <description>T80/A 5mg FDC tablet, Concomitant use, Concomitant use, T80/A 5mg FDC tablet</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence B</title>
          <description>Concomitant use, T80/A 5mg FDC tablet, T80/A 5mg FDC tablet, Concomitant use</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Crossover Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Crossover Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Sequence A</title>
        </group>
        <group group_id="B2">
          <title>Treatment Sequence B</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.1" spread="3.3"/>
                    <measurement group_id="B2" value="24.5" spread="3.8"/>
                    <measurement group_id="B3" value="24.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-tz</title>
        <description>Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. Therefore, the number of observed PK parameter were 32+32+31+31=126 in T80/A5 FDC tablet and T80 + A5, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5 mg FDC Tablet</title>
          </group>
          <group group_id="O2">
            <title>T80mg Tablet and A5 mg Tablet in Concomitant Use</title>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz</title>
          <description>Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
          <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. Therefore, the number of observed PK parameter were 32+32+31+31=126 in T80/A5 FDC tablet and T80 + A5, respectively.</population>
          <units>ng*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1970" spread="67.9"/>
                    <measurement group_id="O2" value="1950" spread="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between T80/A 5mg FDC tablet and T80mg / A5 mg tablet in concomitant use</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>100.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.7</ci_lower_limit>
            <ci_upper_limit>104.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>maximum measured concentration of Telmisartan in plasma</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. Therefore, the number of observed PK parameter were 32+32+31+31=126 in T80/A5 FDC tablet and T80 + A5, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5 mg FDC Tablet</title>
          </group>
          <group group_id="O2">
            <title>T80mg Tablet and A5 mg Tablet in Concomitant Use</title>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum measured concentration of Telmisartan in plasma</description>
          <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. Therefore, the number of observed PK parameter were 32+32+31+31=126 in T80/A5 FDC tablet and T80 + A5, respectively.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471" spread="88.1"/>
                    <measurement group_id="O2" value="484" spread="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between T80/A 5mg FDC tablet and T80mg / A5 mg tablet in concomitant use</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>97.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>87.2</ci_lower_limit>
            <ci_upper_limit>108.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞</title>
        <description>area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5 mg FDC Tablet</title>
          </group>
          <group group_id="O2">
            <title>T80mg Tablet and A5 mg Tablet in Concomitant Use</title>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity</description>
          <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
          <units>ng*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2410" spread="60.4"/>
                    <measurement group_id="O2" value="2300" spread="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between T80/A 5mg FDC tablet and T80mg / A5 mg tablet in concomitant use</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>101.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.3</ci_lower_limit>
            <ci_upper_limit>105.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>time from dosing to the maximum concentration of Telmisartan in plasma</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. Therefore, the number of observed PK parameter were 32+32+31+31=126 in T80/A5 FDC tablet and T80 + A5, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5 mg FDC Tablet</title>
          </group>
          <group group_id="O2">
            <title>T80mg Tablet and A5 mg Tablet in Concomitant Use</title>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>time from dosing to the maximum concentration of Telmisartan in plasma</description>
          <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. Therefore, the number of observed PK parameter were 32+32+31+31=126 in T80/A5 FDC tablet and T80 + A5, respectively.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" spread="0.500" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O2" value="0.750" spread="0.250" lower_limit="0.250" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between T80/A 5mg FDC tablet and T80mg / A5 mg tablet in concomitant use</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>110.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.8</ci_lower_limit>
            <ci_upper_limit>124.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz</title>
        <description>terminal rate constant of Telmisartan in plasma</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5 mg FDC Tablet</title>
          </group>
          <group group_id="O2">
            <title>T80mg Tablet and A5 mg Tablet in Concomitant Use</title>
          </group>
        </group_list>
        <measure>
          <title>λz</title>
          <description>terminal rate constant of Telmisartan in plasma</description>
          <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
          <units>/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0297" spread="52.5"/>
                    <measurement group_id="O2" value="0.0326" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between T80/A 5mg FDC tablet and T80mg / A5 mg tablet in concomitant use</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>91.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>85.6</ci_lower_limit>
            <ci_upper_limit>97.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>terminal half-life of Telmisartan in plasma</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5 mg FDC Tablet</title>
          </group>
          <group group_id="O2">
            <title>T80mg Tablet and A5 mg Tablet in Concomitant Use</title>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>terminal half-life of Telmisartan in plasma</description>
          <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="52.5"/>
                    <measurement group_id="O2" value="21.3" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between T80/A 5mg FDC tablet and T80mg / A5 mg tablet in concomitant use</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>109.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>102.4</ci_lower_limit>
            <ci_upper_limit>116.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRTpo</title>
        <description>mean residence time of Telmisartan in the body after oral administration</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5 mg FDC Tablet</title>
          </group>
          <group group_id="O2">
            <title>T80mg Tablet and A5 mg Tablet in Concomitant Use</title>
          </group>
        </group_list>
        <measure>
          <title>MRTpo</title>
          <description>mean residence time of Telmisartan in the body after oral administration</description>
          <population>One subject who discontinued the study on period 2 was excluded from Pharmacokinetic data set. In analysis only used data which the parameter can be calculated.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="56.2"/>
                    <measurement group_id="O2" value="19.9" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between T80/A 5mg FDC tablet and T80mg / A5 mg tablet in concomitant use</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>109.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>101.5</ci_lower_limit>
            <ci_upper_limit>117.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing the informed consent onwards through the observational phase</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Sequence A</title>
          <description>T80/A 5mg FDC tablet, Concomitant use, Concomitant use, T80/A 5mg FDC tablet</description>
        </group>
        <group group_id="E2">
          <title>Treatment Sequence B</title>
          <description>Concomitant use, T80/A 5mg FDC tablet, T80/A 5mg FDC tablet, Concomitant use</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

